Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
122509702 | 12250970 | 2 | F | 2016 | 20160726 | 20160409 | 20160826 | PER | US-TEVA-647124USA | TEVA | 0.00 | F | Y | 0.00000 | 20160826 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
122509702 | 12250970 | 1 | PS | COPAXONE | GLATIRAMER ACETATE | 1 | Subcutaneous | C42189 | 20622 | 40 | MG | INJECTION | TIW | ||||||
122509702 | 12250970 | 2 | C | Complex B50 | 2 | Unknown | 0 | ||||||||||||
122509702 | 12250970 | 3 | C | VITAMIN D | CHOLECALCIFEROL | 1 | Unknown | 0 | |||||||||||
122509702 | 12250970 | 4 | C | GLUCOSAMINE | GLUCOSAMINE | 1 | Unknown | 0 | |||||||||||
122509702 | 12250970 | 5 | C | OMEGA 3 | OMEGA-3 FATTY ACIDS | 1 | Unknown | 0 | |||||||||||
122509702 | 12250970 | 6 | C | CALCIUM | CALCIUM | 1 | Unknown | 0 | |||||||||||
122509702 | 12250970 | 7 | C | NORVASC | AMLODIPINE BESYLATE | 1 | Unknown | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
122509702 | 12250970 | 1 | Multiple sclerosis |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
122509702 | 12250970 | Fatigue | |
122509702 | 12250970 | Increased appetite | |
122509702 | 12250970 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |